July 21, 2023
A head-spinning spree of rulings and new lawsuits in 2023's first half is reverberating across the health care industry and auguring a dizzying denouement in the year's final months that may well upend assumptions about drug prices and approvals, the False Claims Act and the powers of federal regulators.
July 18, 2023
Johnson & Johnson unit Janssen Pharmaceuticals has launched a suit to challenge a system allowing Medicare to negotiate prescription drug prices under a federal inflation deterrent, marking at least the sixth lawsuit to fight the provision.